טבע תציג ניתוחים חדשים של fremanezumab ונתונים אודות נטל מיגרנה הספציפיים למדינות בקונגרס העולמי ה -24 לנוירולוגיה

6 דקות
אוקטובר 24, 2019
- חדשות

ארבע מצגות בעל פה ושמונה פוסטרים מדגישים את המחויבות של טבע לחולי מיגרנה ברחבי העולם

ירושלים, 24 באוקטובר 2019 - טבע תעשיות פרמצבטיות בע"מ (NYSE ו- TASE: TEVA) הודיעה היום כי 12 ניתוחים חדשים יוצגו בקונגרס העולמי ה -24 לנוירולוגיה (WCN), שיתקיים בדובאי, איחוד האמירויות הערביות ב- 27 באוקטובר -31, 2019. בין הניתוחים טבע תציג את יעילותו של fremanezumab לפי מדינה באחת משלוש המצגות בעל-פה מתוך FOCUS, המחקר הבינלאומי, הרב-מרכזי, האקראי, מבוקר פלסבו, שלב IIIb. החברה תספק גם נתונים במצגת בעל פה על נטל המיגרנה ברחבי סין, ישראל, רוסיה, דרום קוריאה וטורקיה, וכן במצגת פוסטרים בהערכת הנטל של מיגרנה ברחבי ארגנטינה, ברזיל, צ'ילה ומקסיקו

ג'ושוע מ. כהן, MD, MPH, FAHS, מנהל רפואי גלובלי למיגרנה וכאבי ראש בטבע אמר, "כחלק מהמחקר הבינלאומי הגדול ביותר עד כה שהעריך חולים עם תגובה לא מספקת לשיעורים מרובים של טיפולי מיגרנה מונעים, אנו גאים להציג את תוצאות FOCUS בפני קהל עולמי. מגוון רחב של נתונים זה מדגיש את המחויבות הגלובלית שלנו לסייע לחולים עם טיפול במיגרנה, כמו גם את המנהיגות שלנו בתחום הטיפולי של מערכת העצבים המרכזית.

מחקר FOCUS העריך את היעילות והבטיחות של טיפול רבעוני וחודשי ב -fremanezumab בהשוואה לפלסבו בקרב חולים בוגרים עם מיגרנה ותיעדו תגובה לא מספקת ל 2-4 שיעורים של טיפולים מונעים קודמים. נתוני FOCUS נוספים שיוצגו ב- WCN כוללים נתונים על היפוך ממיגרנה כרונית לאפיזודית, נתונים על הסיכויים להשגת שיעורי תגובה משמעותיים ב- fremanezumab בהשוואה לפלסבו, וניתוח המדגים ירידה משמעותית בשכיחות ההילה במיגרנה בקרב חולים שטופלו עם fremanezumab לעומת פלצבו.

להלן מבחר תקצירים שנתקבלו להצגה במהלך IHC השנה:

Oral Presentations:

[WCN19-1409] Efficacy of fremanezumab by country in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study (October 30, 2019, 9:10 GST)
[WCN19-1417] Burden of migraine across China, Israel, Russia, South Korea, and Turkey: Results of a systematic literature review (October 30, 2019, 9:20 GST)
[WCN19-1330] Odds ratios for response to fremanezumab in migraine patients with inadequate response to 2-4 migraine preventive medication classes: Results of the FOCUS Phase 3b study (October 30, 2019, 10:10 GST)
[WCN19-1372] Reversion from chronic to episodic migraine in patients with inadequate response to 2-4 classes of migraine preventive treatments in the FOCUS Phase 3b study (October 30, 2019, 10:20 GST)

Poster Presentations:

[WCN19-1351] Reduction in migraine days with aura with fremanezumab in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the FOCUS study (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1380] Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1432] Burden of migraine across Argentina, Brazil, Chile, and Mexico: Results from a systematic literature review (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1590] Reductions in migraine and headache days in chronic migraine patients with and without prior migraine preventive treatment use: subgroup analysis of the HALO CM study (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1043] Long-term effect of fremanezumab on the overall number of headache hours and on the duration of remaining headaches in patients with chronic or episodic migraine (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1339] Fremanezumab impact on disability and MSQoL in patients with inadequate response to 2-4 classes of preventive medications who reverted from chronic to episodic migraine (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1504] Reductions in headache impact test (HIT-6) scores with fremanezumab and erenumab among patients with episodic migraine (EM) and 2-4 prior treatment failures: a network meta-analysis (October 30, 2019, 9:30 – 15:00 GST)
[WCN19-1574] Reduction in acute headache medication use with fremanezumab in chronic migraine patients by prior migraine preventive treatment use: subgroup analysis of the HALO CM study (October 30, 2019, 9:30 – 15:00 GST)

About FOCUS

The Phase IIIb FOCUS study is a multicentre, randomised, double-blind, parallel-group, placebo-controlled study that evaluated the efficacy, safety, and tolerability of quarterly and monthly treatment with fremanezumab, compared to placebo. Adult patients with chronic migraine or episodic migraine who have responded inadequately to 2-4 classes of prior preventive treatments were enrolled in the study.

Inadequate response is defined as: lack of efficacy after at least three months of therapy at a stable dose; or the patient cannot tolerate the drug; or the drug is contraindicated; or the drug is not suitable for the patient. The classes of prior preventive medications include: beta-blockers, anticonvulsants, tricyclics, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, and valproic acid.

In the study, chronic migraine and episodic migraine patients were randomised in blinded-fashion 1:1:1 into one of three treatment groups – a quarterly dosing regimen, a monthly dosing regimen or matching placebo. An open-label extension of three months (weeks 13-24) followed the placebo-controlled portion of the study.

About the HALO Clinical Research Program

The Phase III HALO EM and CM studies were 16-week, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies to compare the safety, tolerability, and efficacy of four dose regimens (two for EM [quarterly and monthly] and two for CM [quarterly and monthly]), of subcutaneous fremanezumab compared to placebo in adults with episodic and chronic migraine. The studies consisted of a screening visit, a 28-day run-in period, and a 12-week (84-day) treatment period, including a final evaluation at week 12 (end-of-treatment [EOT] visit, four weeks [28 days] after the final dose of study drug).

In the EM study, 875 patients were enrolled (294, 291, 290 patients in the placebo, quarterly, and monthly dose groups, respectively). Patients were randomised in a 1:1:1 ratio to receive subcutaneous injections of fremanezumab at 225 mg for three months (monthly dose regimen), fremanezumab at 675 mg at initiation followed by placebo for two months (quarterly dose regimen), or three monthly doses of matching placebo. The primary efficacy endpoint of the EM study was the mean change from baseline (28-day run-in period) in the monthly average number of migraine days during the 12-week period after the first dose of fremanezumab.
In the CM study, 1,130 patients were randomised (375, 376, 379 patients in the placebo, quarterly, and monthly groups, respectively). Patients were randomised in a 1:1:1 ratio to receive subcutaneous injections of fremanezumab at 675 mg at initiation followed by monthly 225 mg for two months (monthly dose regimen), fremanezumab at 675 mg at initiation followed by placebo for two months (quarterly dose regimen), or three monthly doses of matching placebo. The primary efficacy endpoint of the CM study was the mean change from baseline (28-day run-in period) in the monthly average number of headache days of at least moderate severity during the 12-week period after the first dose of fremanezumab.

אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE & TASE: TEVA) מפתחת ומייצרת תרופות לשיפור חייהם של אנשים מזה למעלה ממאה שנה. אנו מובילים גלובליים בגנריקה ובתרופות ייחודיות, עם פורטפוליו הכולל יותר מ- 2,400 מוצרים בכמעט כל תחום טיפולי. בכל יום, קרוב ל-200 מיליון אנשים ברחבי העולם נוטלים תרופה של טבע, הודות לאחת ממערכות התפעול הגדולות והמורכבות בתעשייה הפרמצבטית. נוסף על מעמדנו המבוסס בגנריקה, יש לנו פעילות מחקר חדשני משמעותית התומכת בפורטפוליו המוצרים הייחודיים והביופרמצבטיים הגדל שלנו. למידע נוסף על החברה, בקרו באתר www.Teva.co.il

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

uncertainties relating to the potential benefits and success of our new structure and recent senior management changes as well as the potential success and our ability to effectively execute a restructuring plan;
our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”); our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and as a result of increased governmental pricing pressures; and our ability to take advantage of high-value biosimilar opportunities;
our specialty medicines business, including: competition for our specialty products, especially Copaxone^®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a downgrade of our credit ratings;
our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel;the restructuring of our manufacturing network, including potential related labor unrest; the impact of continuing consolidation of our distributors and customers; variations in patent laws that may adversely affect our ability to manufacture our products; our ability to consummate dispositions on terms acceptable to us; adverse effects of political or economic instability, major hostilities or terrorism on our significant worldwide operations; and our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions;
compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; the significant increase in our intangible assets, which may result in additional substantial impairment charges; potentially significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.